Lineage Cell Therapeutics Q1 2024 GAAP EPS $(0.04), Inline, Sales $1.444M Beat $1.359M Estimate
Lineage Cell Therapeutics Q1 2024 GAAP EPS $(0.04), Inline, Sales $1.444M Beat $1.359M Estimate
Lineage Cell Therapeutics 2024年第一季度每股收益为0.04美元（0.04美元），直列式，销售额为14.44亿美元，超过13.59万美元的预期
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 33.33 percent decrease over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $1.444 million which beat the analyst consensus estimate of $1.359 million by 6.22 percent. This is a 39.48 percent decrease over sales of $2.386 million the same period last year.
Lineage Cell Therapeutics（美国证券交易所股票代码：LCTX）公布的季度亏损为每股0.04美元，符合分析师的共识预期。与去年同期每股亏损0.03美元（0.03）相比，下降了33.33％。该公司公布的季度销售额为14.44亿美元，比分析师普遍预期的13.59万美元高出6.22％。这比去年同期的238.6万美元的销售额下降了39.48％。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。